Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies (NCT05142722)
PREVAIL
This trial is No longer recruiting
Registration number NCT05142722
Program & service
This trial is being run with the Heart & Lung service, and as part of the Cardiology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor James Shaw
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR